Sanofi/Aventis Merger Would Prevent Plavix-Style Profit-Sharing Agreements, CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi downplays Aventis' sales force as a major reason for merging with its French neighbor. Sanofi has nine late-stage products, including the smoking cessation/obesity agent rimonabant and antiarrhythmic dronedarone.